Q4 2025 saw 2% sales growth adjusted for currency, with Medical Solutions up 5% and Engineered Solutions down 1%. Margins improved year-over-year, but were impacted by currency headwinds and higher material costs. CapEx and M&A activity remain elevated.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.